Literature DB >> 11152924

Vaginal preparation with povidone iodine and postcesarean infectious morbidity: a randomized controlled trial.

V C Reid1, K E Hartmann, M MCMahon, E P Fry.   

Abstract

OBJECTIVE: To determine whether vaginal preparation with povidone iodine before cesarean decreased the incidence of postpartum infectious morbidity.
METHODS: Participants were randomly assigned to vaginal preparation with povidone iodine (n = 247) or no preparation (n = 251). Postpartum infectious morbidity included fever, defined as temperature of 38C or greater after the day of surgery; endometritis, defined as fever with abdominal or uterine tenderness and initiation of intravenous antibiotics; and wound separation, defined as disruption of the abdominal incision that required wound care. We calculated overall rates of postpartum infectious morbidity, relative risks (RR), and 95% confidence intervals (CI) for the effect of vaginal preparation. As designed and reported, the trial had at least 80% power to detect a 10% or greater absolute difference in rates of overall infectious morbidity, fever, and endometritis (two-tailed, alpha = 0.05).
RESULTS: There was no difference between groups in maternal age, parity, race, education, prior cesarean, type of anesthesia, labor before current cesarean, number of vaginal examinations during labor, internal monitoring, prophylactic antibiotic use, gestational age at delivery, or payment status. Excluding 68 women with chorioamnionitis, incidence of postoperative fever was 19.3%, endometritis 7.2%, and wound separation 7.0%. Vaginal preparation with povidone iodine before cesarean had no effect on risk for fever (RR 1.1, 95% CI 0.8, 1.6), endometritis (RR 1.6, 95% CI 0.8, 3.1), or wound separation (RR 0.6, 95% CI 0.3, 1.3).
CONCLUSION: Vaginal preparation with povidone iodine before cesarean had no effect on the incidence of fever, endometritis, or wound infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152924     DOI: 10.1016/s0029-7844(00)01087-5

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  7 in total

1.  Effect of Normal Saline on Cleaning Uterine Cavity During Cesarean Delivery.

Authors:  Lobat Jafarzadeh; Hajar Hojjati
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Does povidone-iodine application in surgical procedures help in the prevention of surgical site infections? An updated meta-analysis.

Authors:  Lihua Shi; Li Cai; Fen Wan; Yali Jiang; Rupshikha Choudhury; Sanjay Rastogi
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2022-01-09       Impact factor: 1.627

3.  Risk factors for endometritis after low transverse cesarean delivery.

Authors:  Margaret A Olsen; Anne M Butler; Denise M Willers; Gilad A Gross; Preetishma Devkota; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-01       Impact factor: 3.254

4.  Institutional Protocols for Vaginal Preparation With Antiseptic Solution and Surgical Site Infection Rate in Women Undergoing Cesarean Delivery During Labor.

Authors:  Mauricio La Rosa; Victoria Jauk; George Saade; Kim Boggess; Sherri Longo; Erin A S Clark; Sean Esplin; Kirsten Cleary; Ronald Wapner; Kellett Letson; Michelle Y Owens; Sean Blackwell; Jeff M Szychowski; William W Andrews; Alan T Tita
Journal:  Obstet Gynecol       Date:  2018-08       Impact factor: 7.661

Review 5.  Surgical site infections after cesarean delivery: epidemiology, prevention and treatment.

Authors:  Tetsuya Kawakita; Helain J Landy
Journal:  Matern Health Neonatol Perinatol       Date:  2017-07-05

Review 6.  Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections.

Authors:  David M Haas; Sarah Morgan; Karenrose Contreras; Savannah Enders
Journal:  Cochrane Database Syst Rev       Date:  2018-07-17

7.  Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections.

Authors:  David M Haas; Sarah Morgan; Karenrose Contreras; Savannah Kimball
Journal:  Cochrane Database Syst Rev       Date:  2020-04-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.